Olmecip Trio Tablet contains a combination of Hydrochlorothiazide 12.5 mg and Olmesartan Medoxomil 20 mg, formulated for the management of hypertension. Olmesartan Medoxomil is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting vasoconstriction and aldosterone secretion, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide is a thiazide diuretic that promotes the excretion of sodium and water by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, thereby reducing plasma volume and peripheral vascular resistance. The combination of these two agents provides complementary mechanisms to achieve effective blood pressure control, reducing the risk of cardiovascular events such as stroke and myocardial infarction. Olmecip Trio is indicated for patients who require more than one antihypertensive agent to achieve target blood pressure levels. It should be used under medical supervision, with monitoring of renal function, electrolytes, and blood pressure. Caution is advised in patients with renal impairment, electrolyte imbalances, or hypersensitivity to sulfonamides. Adverse effects may include dizziness, hypotension, hyperkalemia, and electrolyte disturbances. This medication should be taken as prescribed, and patients should report any unusual symptoms to their healthcare provider promptly.